知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

1379 条记录 (耗时 0.064 秒)

    Targeting of SALL4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS)
    82.
    发明申请
    Targeting of SALL4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS) 失效
    靶向SALL4用于治疗和诊断与骨髓增生异常综合征（MDS）相关的增殖性疾病

    公开(公告)号：US20070174923A1

    公开(公告)日：2007-07-26

    申请号：US11606619

    申请日：2006-11-29

    申请人： Yupo Ma

    发明人： Yupo Ma

    IPC分类号： A01K67/027 ,  C07K16/30 ,  C07K14/82 ,  C12Q1/68 ,  G01N33/574 ,  A61K39/395

    CPC分类号： C07K16/18 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/0331 ,  A01K2267/0381 ,  C07K14/4705 ,  C12N15/8509 ,  G01N33/5011 ,  G01N33/57426 ,  G01N33/57492

    摘要： The present invention discloses nucleic acids, proteins, and antibodies for SALL4 (including isoforms SALL4A, SALL4B, and SALL4C), a zinc finger transcriptional factor. Further, methods are disclosed which demonstrate that constitutive expression of SALL4 increases leukemogenic potential in cells of model animal systems. Moreover, constitutive expression of select isoforms (e.g., SALL4B) in transgenic mice demonstrate that these animals develop myelodysplastic syndrome (MDS)-like signs and symptoms, including subsequent acute myeloid leukemia (AML), which is transplantable. The disclosure also provides methods for identifying and purifying embryonic stem cells, adult stem cells, cancer stem cells, including leukemia stem cells, methods for identifying substances which bind to and/or modulate SALL4, methods for diagnosing MDS in a subject, and methods of treating a subject presenting MDS.

    摘要翻译： 本发明公开了用于SALL4（包括同工型SALL4A，SALL4B和SALL4C）（锌指转录因子）的核酸，蛋白质和抗体。 此外，公开了表明SALL4的组成型表达增加模型动物系统的细胞中的白血病发生潜力的方法。 此外，转基因小鼠中选择性异构体（例如SALL4B）的组成型表达证明这些动物发生骨髓增生异常综合征（MDS）样迹象和症状，包括可移植的随后的急性骨髓性白血病（AML）。 本公开还提供了用于鉴定和纯化胚胎干细胞，成体干细胞，癌症干细胞（包括白血病干细胞）的方法，用于鉴定结合和/或调节SALL4的物质的方法，用于诊断受试者的MDS的方法和方法 治疗呈现MDS的科目。

    Composition, splice variants and methods relating to ovarian specific genes and proteins
    83.
    发明申请
    Composition, splice variants and methods relating to ovarian specific genes and proteins 审中-公开
    与卵巢特异性基因和蛋白质相关的组合物，剪接变体和方法

    公开(公告)号：US20070154886A1

    公开(公告)日：2007-07-05

    申请号：US10537743

    申请日：2003-12-08

    申请人： Roberto Macina ,  Leah Turner ,  Yongming Sun ,  Shu-Hui Liu ,  Huei-Mei Chen

    发明人： Roberto Macina ,  Leah Turner ,  Yongming Sun ,  Shu-Hui Liu ,  Huei-Mei Chen

    IPC分类号： C12Q1/68 ,  G01N33/574 ,  C07H21/04 ,  C12P21/06 ,  C07K14/82 ,  C07K16/30

    CPC分类号： C07K14/82 ,  C07K14/47 ,  G01N33/57449

    摘要： The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and non-cancerous disease states in ovarian, identifying ovarian tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered ovarian tissue for treatment and research.

    摘要翻译： 本发明涉及存在于正常和肿瘤性卵巢细胞中的新鉴定的核酸分子和多肽，包括核酸和多肽的片段，变体和衍生物。 本发明还涉及本发明多肽的抗体，以及本发明多肽的激动剂和拮抗剂。 本发明还涉及含有本发明的核酸分子，多肽，抗体，激动剂和拮抗剂以及使用这些组合物的方法的组合物。 这些用途包括鉴定，诊断，监测，分期，成像和治疗卵巢癌和非癌性疾病状态，确定卵巢组织，监测和鉴定和/或设计本发明多肽的激动剂和拮抗剂。 用途还包括基因治疗，转基因动物和细胞的生产，以及用于治疗和研究的工程化卵巢组织的生产。

    Bace455, an alternative splice variant of the human beta-secretase
    85.
    发明申请
    Bace455, an alternative splice variant of the human beta-secretase 失效
    Bace455是人β-分泌酶的替代剪接变体

    公开(公告)号：US20070142277A1

    公开(公告)日：2007-06-21

    申请号：US10578493

    申请日：2004-11-05

    申请人： Laurent Desire

    发明人： Laurent Desire

    IPC分类号： A61K38/55 ,  A61K48/00 ,  C12Q1/68 ,  C07H21/04 ,  C12P21/06 ,  C07K14/82

    CPC分类号： C12N9/6421 ,  A61K38/00

    摘要： The present invention relates generally to the fields of genetics, biochemistry, medicinal chemistry and medicine. The present invention more particularly discloses the identification of a human gene variant involved in neuropathological conditions, and methods for the diagnosis, prevention and treatment of such diseases and related disorders, as well as for the screening of therapeutically active drugs. The present invention relates to catalytically active beta-secretase (Memapsin2, BACE) variants, and nucleic acids encoding them. The invention is useful in the identification of agents that inhibit the activity of a particular BACE isoform and thus agents and therapies affecting the genesis, development or progression of neuropathological conditions, including Alzheimer's disease and dementia.

    摘要翻译： 本发明一般涉及遗传学，生物化学，药物化学和医学领域。 本发明更具体地公开了鉴定涉及神经病理学病症的人基因变体，以及用于诊断，预防和治疗这些疾病和相关疾病以及用于筛选治疗活性药物的方法。 本发明涉及催化活性β-分泌酶（Memapsin2，BACE）变体和编码它们的核酸。 本发明可用于鉴定抑制特定BACE同种型的活性的药剂，因此可用于影响神经病理学病症（包括阿尔茨海默病和痴呆）的发生，发展或进展的药剂和疗法。

    Methods
    87.
    发明申请
    Methods 审中-公开
    方法

    公开(公告)号：US20070110759A1

    公开(公告)日：2007-05-17

    申请号：US11434320

    申请日：2006-05-11

    申请人： Quentin Sattentau ,  Peter Openshaw ,  Amin Moghaddam ,  Wieslawa Olszewska

    发明人： Quentin Sattentau ,  Peter Openshaw ,  Amin Moghaddam ,  Wieslawa Olszewska

    IPC分类号： A61K39/00 ,  C08B37/00 ,  C07K14/82

    CPC分类号： A61K39/00 ,  A61K39/35 ,  A61K2039/57

    摘要： The presence of aldehydic groups on proteins and lipoproteins is associated with various pathological conditions such as atherosclerosis, diabetes and alcoholic liver disease. Respiratory syncytial virus (RSV) is a major cause of severe respiratory disease in infants and the elderly. RSV vaccine research has been impeded because a formalin-inactivated vaccine used in the 1960s predisposed infants to enhanced disease following subsequent natural infection. The molecular basis for the vaccine-induced hypersensitivity has not, however, been elucidated. We show here that addition of reactive carbonyl groups to ovalbumin (OVA) by treatment with glycolaldehyde or formaldehyde increases the protein's immunogenicity in mice, and biases the immune response towards a Th2-type response. The increased immunogenicity and the Th2-type response can both be abrogated by reductive elimination of the reactive carbonyl groups. We demonstrate that RSV inactivated by formaldehyde (FI-RSV), following a protocol used previously to prepare the vaccine, contains reactive carbonyl groups. Using a well-established model of FI-RSV vaccine-induced pathology, immunisation of mice with FI-RSV and subsequent challenge of the mice with live RSV induced Th2-type responses, lung eosinophilia and weight loss that were abrogated by reductive elimination of the reactive carbonyl groups. We thus propose that the addition of reactive carbonyl groups to RSV during inactivation is the major mechanism that drives the Th2-immune response and associated pathology. Moreover, we suggest that the addition of reactive carbonyl groups to other antigens, including vaccines, may be responsible for other hypersensitive and allergic reactions described in the literature.

    摘要翻译： 蛋白质和脂蛋白上醛基的存在与各种病理状况如动脉粥样硬化，糖尿病和酒精性肝病有关。 呼吸道合胞病毒（RSV）是婴幼儿严重呼吸系统疾病的主要原因。 RSV疫苗研究受到阻碍，因为二十世纪六十年代使用的福尔​​马林灭活疫苗使婴儿在随后的自然感染后发生增强的疾病。 然而，疫苗诱导的超敏反应的分子基础尚未阐明。 我们在这里显示，通过用乙醇醛或甲醛处理向卵白蛋白（OVA）中加入反应性羰基增加了蛋白质在小鼠中的免疫原性，并且将免疫应答偏向Th2型反应。 增加的免疫原性和Th2型反应都可以通过还原性消除反应性羰基来消除。 我们证明根据以前用于制备疫苗的方案，由甲醛（FI-RSV）灭活的RSV含有活性羰基。 使用FI-RSV疫苗诱导的病理学的成熟模型，用FI-RSV免疫小鼠，随后用活RSV诱导的Th2型反应对小鼠进行攻击，肺嗜酸粒细胞增多和体重减轻，通过还原消除 反应性羰基。 因此，我们建议在灭活期间向RSV中添加活性羰基是驱动Th2免疫应答和相关病理学的主要机制。 此外，我们建议向其他抗原（包括疫苗）添加活性羰基可能是文献中描述的其他过敏反应和过敏反应的原因。

    Tumor antigen
    90.
    发明申请
    Tumor antigen 有权

    公开(公告)号：US20070071767A1

    公开(公告)日：2007-03-29

    申请号：US11543087

    申请日：2006-10-05

    申请人： Kyogo Itoh

    发明人： Kyogo Itoh

    IPC分类号： C07H21/04 ,  C12P21/06 ,  A61K39/00 ,  C07K14/82

    CPC分类号： C07K14/4748 ,  A61K39/00 ,  A61K2039/53 ,  C07K14/47

    摘要： Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises the polynucleotide are provided.